Details for Patent: 10,927,142
✉ Email this page to a colleague
Which drugs does patent 10,927,142 protect, and when does it expire?
Patent 10,927,142 protects BREXAFEMME and is included in one NDA.
This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 10,927,142
| Title: | Salts and polymorphs of SCY-078 |
| Abstract: | SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078. |
| Inventor(s): | Zhang; Yi (Suzhou, CN) |
| Assignee: | SCYNEXIS, INC. (Jersey City, NJ) |
| Application Number: | 16/437,693 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,927,142
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,927,142
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Denmark | 3247711 | ⤷ Sign Up | |||
| Eurasian Patent Organization | 036874 | ⤷ Sign Up | |||
| Eurasian Patent Organization | 201791645 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
